MQS Management LLC Acquires Shares of 2,943 AbbVie Inc. $ABBV

MQS Management LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 2,943 shares of the company’s stock, valued at approximately $672,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. Legal & General Group Plc grew its stake in AbbVie by 4.3% in the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP grew its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Amundi grew its stake in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after purchasing an additional 408,426 shares during the period. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ABBV. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Canaccord Genuity Group upped their price target on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Price Performance

Shares of NYSE ABBV opened at $216.02 on Friday. AbbVie Inc. has a one year low of $181.71 and a one year high of $244.81. The business’s fifty day moving average price is $208.72 and its 200-day moving average price is $219.68. The stock has a market capitalization of $381.66 billion, a PE ratio of 106.41, a P/E/G ratio of 0.74 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, equities analysts expect that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.